FT: The Evidence From Chile Says Sinovac’s Vaccine is Working

Despite earlier concerns over its low efficacy rate, the Chinese-made Sinovac COVID-19 vaccine appears to be performing well in its largest test to date in Chile, according to the findings by the Financial Times’ Senior Data-Visualization Journalist John Burn-Murdoch.

Sinovac’s 50.4% efficacy rate that was derived from phase three clinical trials in Brazil, related to mild cases only. What Burn-Murdoch’s reporting shows is that the vaccine is successfully protecting people from becoming seriously ill and keeping them out of the intensive care unit.

Read more on the efficacy performance of Sinovac and other vaccines on the FT website.

  • Get a daily email packed with the latest China-Africa news and analysis.
  • Read exclusive insights on the key trends shaping China-Africa relations.
  • Connect with leading professionals on the China- Africa Experts Network.

You've reached your free monthly article limit.

Subscribe today for unlimited access.

The post FT: The Evidence From Chile Says Sinovac’s Vaccine is Working appeared first on The China Africa Project.



source https://chinaafricaproject.com/2021/04/22/ft-the-evidence-from-chile-says-sinovacs-vaccine-is-working/

Comments

Popular posts from this blog

DR Congo Receives First Shipment of Chinese COVID Vaccines

WEEK IN REVIEW: The G77 Bloc of Countries Together With China To Propose a New “Loss and Damage” Fund at the COP27 Summit

WEEK IN REVIEW: Brazil Warns That Mercosur in Jeopardy if Uruguay Signs a Free Trade Agreement With China